The team at Metronomia is proud to announce our involvement in a recently launched COVID-19 clinical study. The sponsor, clinical CRO, trial sites, regulators and Metronomia worked intensively and dedicatedly together to achieve extraordinary approval and trial initiation timelines.

Through Metronomia’s experience and agility, we supported the rapid setup of this study in no more than eight working days of receipt of a draft protocol. At the end of this 8-day period, the first patient was randomized.

Our key contributions thus far include:

• Development of a phase II/III statistical design within 3 days
• Launch of a fully functional eCRF within 5 working days from receipt of draft protocol
• Set-up of fully integrated IRT technology enabled "First Patient Randomized" within 2 hours of eCRF launch.

Metronomia is a European data science company with 30 years of success in provision of data management and statistical services to pharmaceutical and biotech companies. Our team is exceptional in its commitment and performance, going beyond expectations and industry standards to make critically important projects such as this important COVID-19 study feasible despite challenging conditions and timelines.